Moderna stock hits 4-year high on planned national cancer vaccine effort
Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a beneficiary.
Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a beneficiary.
What's Your Reaction?
